TLDR
- Shares of Boston Scientific fell 2.3% in early Tuesday trading after the company warned investors it would miss both quarterly and annual financial targets.
- The medical device manufacturer linked the shortfall directly to a cybersecurity incident uncovered in late August.
- Prior forecasts called for annual revenue expansion between 5.5% and 6.5%, with adjusted earnings per share ranging from $3.28 to $3.32.
- Year-to-date, BSX has plummeted 50%, with a 55% decline over the trailing twelve months, trading well beneath its $109.50 peak.
- While TD Cowen maintained its Buy recommendation with a $56 target, the optimistic outlook was eclipsed by the company’s official financial warning.
Boston Scientific (BSX) shares slid 2.3% to $46.68 during premarket hours Tuesday following the medical technology company’s official statement that it will probably fall short of revenue and profit projections for both the third quarter and fiscal year 2026.
Boston Scientific Corporation, BSX
The shortfall stems directly from the cybersecurity breach that BSX disclosed on August 25. In a Tuesday regulatory submission, the company stated it is “unlikely to meet” its net sales expansion and adjusted earnings per share targets for the current quarter and full fiscal period.
This represents a more definitive position than the firm’s earlier communications, which indicated that financial ramifications from the breach remained under assessment.
In late July, Boston Scientific projected annual sales expansion of 5.5% to 6.5% with adjusted earnings per share between $3.28 and $3.32. Third-quarter projections called for revenue growth of 3% to 5% and adjusted EPS ranging from 80 to 82 cents.
Analyst consensus had anticipated full-year adjusted earnings of $3.30 per share on revenues of $21.35 billion, with third-quarter expectations at 81 cents per share and $5.26 billion in sales, per FactSet data.
The stock’s struggles extend beyond this recent development. BSX has declined 50% since the start of the year and dropped 55% across the past twelve months. Current trading levels sit significantly below the 52-week peak of $109.50 and approach the 52-week bottom of $42.20.
Analyst Reactions
The guidance withdrawal compounds pressure on shares already facing elevated scrutiny. Argus Research previously cut its rating on BSX from Buy to Hold, citing concerns about expansion trajectories for the Watchman product line and domestic electrophysiology operations.
Following second-quarter results and the initial cybersecurity disclosure, Baird, JPMorgan, and Bank of America each reduced their price objectives.
TD Cowen stood as the solitary optimistic voice, maintaining its Buy rating alongside a $56 price objective. The firm observed that by early September, Boston Scientific’s primary distribution facilities were handling and dispatching products at normal or elevated capacity levels. Despite this encouraging assessment, Tuesday’s formal warning overshadowed any positive sentiment.
What Comes Next
Boston Scientific reported no indication of continued unauthorized system access, though investigations remain ongoing.
The organization anticipates recouping a portion of the lost sales as operations normalize, customer orders get processed, and order backlogs decline.
The comprehensive financial toll from the security incident remains undetermined. Boston Scientific intends to provide a complete operational and financial update, including detailed cyberattack impacts, when it reports third-quarter earnings on October 28.
Other medical technology companies, including Abbott and Medtronic, have similarly confronted cybersecurity challenges in 2026, maintaining pressure on overall sector sentiment.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
